Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

NHS GM care in patients’ homes as NHS virtual wards expand

3

Apr 2026

NHS GM care in patients’ homes as NHS virtual wards expand

When Raymond from Salford was diagnosed with heart failure, he faced an extended hospital stay until NHS Greater Manchester’s virtual ward allowed him to continue his care safely at home. He received twice-daily home visits from the Salford Urgent Response team and had regular contact with clinicians looking after him to discuss and review his care. This meant he could recover more comfortably and quickly being at home.

Study identifies a common hidden genetic cause of neurodevelopmental disorder in children

2

Apr 2026

Study identifies a common hidden genetic cause of neurodevelopmental disorder in children

Researchers identified biallelic variants in RNU2-2 as the cause of a recessive neurodevelopmental disorder marked by intellectual disability, global developmental delay, and frequent seizures. The study suggests this condition may be the most prevalent known recessive neurodevelopmental disorder currently diagnosable by sequencing, with RNA data pointing to a loss-of-expression mechanism.

Pediatric experts say plain yogurt is safe from 6 months and belongs in a baby’s diet

2

Apr 2026

Pediatric experts say plain yogurt is safe from 6 months and belongs in a baby’s diet

An expert panel review says plain, whole yogurt with no added sugar or sweeteners can be introduced from 6 months as part of complementary feeding, provided it does not replace breast milk or infant formula as the main source of nutrition. It also explains that yogurt provides live microorganisms and key nutrients, is generally well tolerated, and helps address common myths about inflammation, mucus, acne, sugar, and safety.

Semaglutide for weight loss was linked to a sharp drop in alcohol use in this case report

2

Apr 2026

Semaglutide for weight loss was linked to a sharp drop in alcohol use in this case report

A 2026 case report describes a 34-year-old man with obesity and alcohol use disorder whose semaglutide treatment for weight loss was associated with a marked drop in drinking over 10 months, with his AUDIT score falling from 27 to 7 and alcohol use dropping from about 15 drinks per week to half a beer per month. The authors frame this as a promising but preliminary finding that adds to growing evidence on GLP-1 drugs and alcohol use, while also stressing that this was a single case and that better AUD screening in family medicine remains important.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.